Detalhe da pesquisa
1.
LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer.
Cell
; 172(4): 825-840.e18, 2018 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29336888
2.
Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests.
Circulation
; 149(3): 192-203, 2024 Jan 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37632469
3.
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
N Engl J Med
; 384(2): 117-128, 2021 01 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33200892
4.
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
N Engl J Med
; 384(2): 129-139, 2021 01 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33200891
5.
Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial.
Arterioscler Thromb Vasc Biol
; 43(8): 1572-1582, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37381988
6.
Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial.
Eur Heart J
; 2023 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36879424
7.
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Circulation
; 146(9): 657-672, 2022 08 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35770629
8.
Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits.
J Vasc Surg
; 77(4): 1107-1118.e2, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36470531
9.
Effect of alirocumab on cataracts in patients with acute coronary syndromes.
BMC Ophthalmol
; 23(1): 279, 2023 Jun 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37328736
10.
Alirocumab after acute coronary syndrome in patients with a history of heart failure.
Eur Heart J
; 43(16): 1554-1565, 2022 04 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34922353
11.
Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial.
Circulation
; 143(11): 1109-1122, 2021 03 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33438437
12.
Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD.
Circulation
; 144(23): 1831-1841, 2021 12 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34637332
13.
Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial.
Am Heart J
; 246: 136-143, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34986394
14.
Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial.
Ann Intern Med
; 174(8): 1065-1072, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34152828
15.
Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial.
Eur Heart J
; 42(39): 4040-4048, 2021 10 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34430972
16.
Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
Circulation
; 141(20): 1608-1617, 2020 05 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32223446
17.
Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial.
Circulation
; 141(8): 624-636, 2020 02 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-31707832
18.
Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial.
Circulation
; 141(23): 1841-1854, 2020 06 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32223318
19.
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
N Engl J Med
; 379(22): 2097-2107, 2018 11 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-30403574
20.
Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial.
Eur Heart J
; 41(42): 4114-4123, 2020 11 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32820320